Bionano Genomics Inc Stock Price, News & Analysis

Bionano Genomics presented findings at the Next-Generation Cytogenomics Symposium, showcasing the Saphyr system's effectiveness in genetic testing. Notable achievements include a 100% concordance in prenatal testing between Saphyr and standard methods like karyotyping, leading to quicker and cost-effective results. Studies across the US, Europe, and China demonstrated Saphyr's reproducibility and ability to resolve rare genetic diseases. Experts from various institutions highlighted Saphyr's advantages in uncovering actionable insights, thereby enhancing diagnostic capabilities in genetic disorders.

Bionano Genomics (Nasdaq: BNGO) announced the publication of findings from the COVID-19 Host Genome Structural Variant Consortium. The study utilized the Saphyr System to identify significant structural variants (SVs) linked to immune responses and disease severity in COVID-19 patients. Analysis of 37 ICU patients revealed that 12 died, while 25 recovered. Notably, a duplication of the STK26 gene was associated with severe illness, suggesting its potential as a prognostic biomarker. The findings highlight Saphyr’s capability in revealing critical genetic insights overlooked by traditional methods.

Bionano Genomics (BNGO) announced its 5-day Next-Generation Cytogenomics Symposium starting January 11, featuring 33 presentations from Saphyr users at leading medical institutions. The event will spotlight applications of optical genome mapping (OGM) for analyzing genetic diseases and blood cancers, alongside studies validating clinical assays. Notably, a session will focus on COVID-19 related genome studies. CEO Erik Holmlin emphasized Saphyr's capability to detect structural variants that traditional methods overlook, potentially increasing diagnostic yields.

Bionano Genomics has announced the pricing of its public offering of 29,016,393 shares at $3.05 each, aiming for gross proceeds of approximately $88.5 million. The offering, set to close on January 12, 2021, includes a 30-day option for underwriters to purchase an additional 4,352,458 shares. Oppenheimer & Co. serves as the sole book-running manager. Shares are offered under a previously filed shelf registration statement. The proceeds are intended to support Bionano’s genomic analysis tools, particularly the Saphyr system.

Bionano Genomics (Nasdaq: BNGO) announced plans for an underwritten public offering of its common stock, with Oppenheimer & Co. Inc. as the sole book-running manager. All shares offered will be sold by Bionano, and underwriters may purchase an additional 15% to cover over-allotments. This offering is under a previously filed "shelf" registration statement, which is effective until August 2023. The company has emphasized potential risks associated with market conditions and closing conditions of the offering, which may affect completion. Further details will be available in the filed prospectus.

Bionano Genomics (Nasdaq: BNGO) announced the publication of a genome analysis of Professor Temple Grandin, highlighting the significance of genetic testing for Autism Spectrum Disorder (ASD). Conducted by Lineagen, Bionano's CLIA-certified diagnostic subsidiary, the study identified novel variants in ASD risk genes, improving clinical management of Grandin's symptoms. Dr. Grandin emphasized the life-changing potential of genetic testing, while CEO Erik Holmlin noted that only 3% of ASD-diagnosed children receive clinical genetic testing, advocating for widespread adoption to inform treatment decisions.

Bionano Genomics (Nasdaq: BNGO) has received a 180-day extension from Nasdaq to comply with the $1.00 minimum bid price requirement, now until June 28, 2021. This decision follows the company's adherence to other continued listing requirements. Nasdaq's notification allows the company to maintain its stock listing while it works towards regaining compliance. Bionano plans to consider a reverse stock split if necessary to achieve this goal. CEO Erik Holmlin expressed optimism about the company's progress and ongoing efforts to advance the Saphyr System in target markets.

Bionano Genomics has announced that Praxis Genomics received CAP accreditation, becoming the first U.S. lab offering a laboratory developed test based on whole genome analysis using the Saphyr system. This test targets postnatal patients with suspected genetic disorders and significantly increases the diagnosis rate compared to traditional methods.

With 18-25% additional diagnoses achievable through Saphyr, the streamlined approach promises a faster and more cost-effective solution for detecting genomic variations. The CEO acknowledged this step as crucial for future reimbursement opportunities.

Bionano Genomics (Nasdaq: BNGO) announced a study showing its optical genome mapping (OGM) detected 72% more large structural variants (SVs) compared to PacBio's sequencing method across 32 human genomes. The OGM technology costs less than $500 per genome, while PacBio's method is estimated at $10,000 to $20,000. The study highlights the clinical relevance of OGM for detecting SVs linked to neurodevelopmental disorders and cancer. Bionano's Saphyr system can produce clinical quality SV calls efficiently, demonstrating superior performance in structural variation detection.